World's Best Scientists 2026 revealed!
Giuseppe Saglio

Giuseppe Saglio

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
120
Citations
74330
World Ranking
3676
National Ranking
106

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Giuseppe Saglio is affiliated with the University of Turin in Italy. Their research focuses primarily on the field of medicine, with particular expertise in hematology, genetics, and molecular biology. The scope of their work also includes rheumatology and public health, environmental, and occupational health.

The scientist's research extensively covers topics related to leukemia and related disorders. The main topics of their work include:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment

Major publication venues where Giuseppe Saglio has contributed include:

  • Blood
  • Leukemia
  • Clinical Lymphoma Myeloma & Leukemia
  • Cancers
  • Journal of Clinical Medicine

Frequent collaborators in their research are:

  • Massimo Breccia
  • Carmen Fava
  • Monica Bocchia
  • Massimiliano Bonifacio
  • Giovanni Caocci

Notable recent publications by Giuseppe Saglio include:

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, 2020, Leukemia
  • Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis, 2021, Leukemia
  • First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis, 2020, Blood Advances
  • Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors, 2020, Leukemia
  • Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial, 2021, Leukemia

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

    Brunangelo Falini;Christina Mecucci;Enrico Tiacci;Myriam Alcalay

  • Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

    J Gabert;E Beillard;V H J van der Velden;W Bi

  • Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

    van Dongen Jj;Macintyre Ea;Gabert Ja;Delabesse E

  • Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program

    E Beillard;N Pallisgaard;V H J van der Velden;W Bi

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Jorge E. Cortes;Giuseppe Saglio;Hagop M. Kantarjian;Michele Baccarani

  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

    A. Hochhaus;G. Saglio;Timothy Hughes;R. A. Larson

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

    Hagop M. Kantarjian;Andreas Hochhaus;Giuseppe Saglio;Carmino De Souza

  • PML targeting eradicates quiescent leukaemia-initiating cells

    Keisuke Ito;Rosa Bernardi;Alessandro Morotti;Sahoko Matsuoka

  • Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy

    Franco Mandelli;Daniela Diverio;Giuseppe Avvisati;Anna Luciano

  • Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

    Simona Soverini;Sabrina Colarossi;Alessandra Gnani;Gianantonio Rosti

Frequent Co-Authors

Giovanni Martinelli
Giovanni Martinelli University of Bologna
Michele Baccarani
Michele Baccarani University of Bologna
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Gianluca Gaidano
Gianluca Gaidano University of Eastern Piedmont Amadeo Avogadro
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Giorgina Specchia
Giorgina Specchia University of Bari Aldo Moro
Jerald P. Radich
Jerald P. Radich Fred Hutchinson Cancer Research Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Richard A. Larson
Richard A. Larson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine offers diverse pathways, many of which can be started or advanced through online study. Online healthcare degrees provide flexibility for working adults and make it easier to take the next step in your medical career. Among the most popular choices are RN to BSN online programs, which help registered nurses earn their bachelor’s degree quickly and affordably from home.

For those seeking advanced practice roles, the cheapest online acute care nurse practitioner programs allow nurses to specialize in acute patient care without taking a break from their current job. Similarly, students balancing work and study may consider the cheapest rn to bsn online programs, which offer lower tuition rates and flexible schedules.

Professionals aiming for leadership or teaching positions can look into the cheapest online dnp programs for the doctoral-level expertise increasingly required in healthcare. Those just starting out, meanwhile, can fast-track their education by comparing reputable rn to bsn online programs. Investing in an online degree could be your first step toward a rewarding future in medicine.

Best Scientists Citing Giuseppe Saglio

Trending Scientists

Recently Published Articles